Endocrine-Related Cancer

Article	Citations
Acknowledgement to reviewers	95
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	73
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	57
Celebrating the 80th anniversary of hormone ablation for prostate cancer	55
Acknowledgement to reviewers	53
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients	47
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	44
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	41
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	40
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	38
Targeting growth hormone in cancer: future perspectives	38
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression	36
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms	36
Update on the genetics of paragangliomas	31
Refining long-term surveillance requirements in patients with differentiated thyroid cancer	31
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	30
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	30
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	28
Radioiodine treatment: an historical and future perspective	28
Metabolically active brown adipose tissue in PPGL: an observational cohort study	28
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	27
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	27
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells	25
Peptide receptor radionuclide therapy in malignant insulinoma	24
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination degradation	24

CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	24
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	23
Antitumor immune response is associated with favorable survival in GEP-NEN G3	23
Gender-affirming care and endocrine-related cancers	22
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	22
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	22
Whole-exome sequencing of rectal neuroendocrine tumors	22
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	21
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	21
Therapy considerations in neuroendocrine prostate cancer: what next?	21
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	20
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	20
Effect of TSH levels during active surveillance of PTMC according to age	20
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	19
From bench to bedside in the sella: translational developments in pituitary tumour genetics	18
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	18
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis	18
Immunotherapy for endocrine tumours: a clinician’s perspective	18
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms	17
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study	17
Exploring stem cell biology in pituitary tumors and derived organoids	16
Steroid profile in patients with breast cancer and in mice treated with mifepristone	16
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	15
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer	15
Acknowledgement to reviewers	14
Inhibition of GATA2 in prostate cancer by a clinically available small molecule	14
Acknowledgement to reviewers	14
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma	14
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors	14
New therapeutic opportunities for women with low-grade serous ovarian cancer	13
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	13
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study	13
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	13
Genetic disorders and insulinoma/glucagonoma	12
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus	12
In vivo and in vitro analysis of functional effects of the SDHD H50R variant	12
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	12
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	12
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	12
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	12
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer	12
Non-pituitary GH regulation of the tissue microenvironment	11
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	11
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	11
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms	11
Sexual dimorphism in thyroid cancer: evidence from preclinical studies	11
Deiodinases in thyroid tumorigenesis	11
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	11
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	11
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	10

International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	10
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	10
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	10
Beyond the three P’s: adrenal involvement in MEN1	10
Mendelian randomization to investigate the link between TSH and thyroid cancer	10
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	10
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis	10
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	10
In memoriam: Charis Eng MD PhD (1962–2024)	10
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	10
MicroRNAs as regulators of tumor metabolism	10
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	9
Surrogate molecular classification of LAR breast cancer in routine workflow	9
Precocious puberty due to intracranial germ cell tumors: a case–control study	9
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer	9
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	9
Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors	9
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	9
Management of high-grade neuroendocrine neoplasms: impact of functional imaging	9
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	9
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	9
mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs	9
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	9
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	9
Risk factors for intraoperative complications in pheochromocytomas	9
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	9
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	9
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors	9
A clinically applicable molecular classification of oncocytic cell thyroid nodules	8
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma	8
Second-generation hormonotherapy in prostate cancer and bone microenvironment	8
Endocrine cancer trends 1990–2021: global disparities and health inequalities	8
Insulinomatosis: new aspects	8
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer	8
Adrenal tumors provide insight into the role of cortisol in NK cell activity	8
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	8
Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic revie	8
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	8
Exploring chromosomal instability and clonal heterogeneity in breast cancer	8
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC	7
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents	7
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer	7
Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature	7
Inflammation-based score in pediatric adrenocortical carcinoma	7
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix	7
A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy	7
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer	7
Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding	7
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	6
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	6
Thyroid status regulates the tumor microenvironment delineating breast cancer fate	6
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	6
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing	6
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	6
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	6
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	6
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation	6
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer	6
Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis	6
SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination	6
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	6
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	6
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	6
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer	6
Second primary cancers and survival among neuroendocrine tumor patients	5
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	5
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	5
Progress and challenges in experimental models for pheochromocytoma and paraganglioma	5
Development and validation of long-acting recombinant human TSH using SAFA technology	5
Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study	5
Therapeutic inhibition of ATR in differentiated thyroid cancer	5
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	5
Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?	5
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	5
Mechanisms of resistance to RET-directed therapies	5
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	5
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	5
New drug delivery strategies targeting the GnRH receptor in breast and other cancers	5
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	5
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	5

The role of membrane mucin MUC4 in breast cancer metastasis	4
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	4
Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era	4
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	4
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	4
Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?	4
Mannose enhances anti-tumor effect of PLX4032 in anaplastic thyroid cancer	4
β-Catenin activation and illicit receptor expression in adrenocortical cells	4
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	4
Autocrine/paracrine growth hormone in cancer progression	4
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?	4
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells	4
Evaluation of modifiable factors and polygenic risk score in thyroid cancer	4
Targeting androgen receptor signaling: a historical perspective	4
Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma	4
Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors	4
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	4
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases	4
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	4
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	4
Pregnancy-associated breast cancer: the influence of gestational age	4
Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer	4
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients	4
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	4
FT3 and FT3/FT4 ratio are decreased and not compensated by levothyroxine treatment in TKI-treated thyroid cancer patients	4
Growth hormone and radiation therapy: friend, foe, or both?	4
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma	4
Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations	3
A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo	3
Genomic testing for RET in the clinic: UK and global perspective	3
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis	3
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis	3
The role of vitamin D in breast cancer risk and progression	3
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review	3
RETRACTION: Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress	3
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome	3
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms	3
PARP inhibitors in advanced prostate cancer: when to use them?	3
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine	3
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	3
Global trends in thyroid cancer 1990–2021: an analysis based on the GBD 2021	3
Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms	3
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET	3
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	3
Talking about sex: erectile dysfunction in the oncology patient	3
Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome	3
Aggressive versus indolent insulinomas: new clinicopathological insights	3
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones	3
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma	3
Oxygen regulates proliferation and phenotype in the RS0 SDH-deficient pheochromocytoma cell line	3
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors	3